• Home
• Corporate Information
  • Management Team
  • • Management Team
    • Board of Directors
    • Committees of the Board
    • Senior Management Team
  • Job Vacancies
  • Links
• Investor Relations
  • Introduction
  • Financial Performance
  • • Key Financial Data
    • Reports & Accounts
  • Share Price
  • Share Charts
  • Securities in Issue
  • Press & News
  • • Press Releases
    • RNS Announcements
  • Shareholder Info
  • • FAQs
    • Financial Calendar
    • Shareholder Services
    • Contacts
    • Info Request
  • News Alert
  • • Alert Service
  • Presentations
  • AIM Rule 26
• Research & Development
  • Introduction
  • Product Pipeline
  • Intellectual Property Rights
  • Cannabinoid Medications
  • • Cannabinoids
    • Mechanism of Action
    • Intoxication
    • Sativex®
    • Cultivation
    • Clinical Trials Review
    • Clinical Publications
  • Cannabinoid Research
    Institute (CRI)
  • Advanced Dispensing
    System (ADS)
  • • Introduction to ADS
    • Drug Addiction
    • Other Applications of ADS
• FAQs
• News & Media
  • Press Releases
  • Notes for Editors
• Sativex®
• United States
• Contact Us

Search

Site Map

Privacy Statement

Disclosure & Disclaimer

		Latest News Tue, 16 Jun 2009 - GW Expands Cannabinoid Research in the Field of Diabetes and Metabolic Disease more Wed, 20 May 2009 - Interim Results For The Six Months Ended 31 March 2009 more Wed, 20 May 2009 - GW Files Sativex® Regulatory Submission more Wed, 01 Apr 2009 - GW Announces £8m Milestone Payment from Almirall more
© GW Pharmaceuticals 2009